Our study aimed to estimated the incidence of KRAS and NRAS mutations (KRAS exons 2/3/4 and NRAS exons 2/3/4) in Moroccan population, to identify the clinicopathological characteristics of KRAS and NRAS gene mutations and to evaluate their prognosis value in colon cancer. This evidence concerns the gene NRAS and malignant colon neoplasm.